Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lobe Sciences Ltd Ordinary Shares GTSIF

Healthcare Drug Manufacturers - Specialty & Generic
Lobe Sciences Ltd is a technology and services company that provides real estate, financial, management, IP, and branding support for the development of transformational medicine. It is working to develop effective psilocybin-based therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder and devices for the efficient application of medications.

Recent & Breaking News (OTCPK:GTSIF)

SmallCapsDaily: Lobe Sciences is a Major Opportunity In the Psychedelics Medicine Industry

Newsfile February 12, 2021

Lobe Sciences Announces Management Changes and New Director

Newsfile January 18, 2021

Lobe Sciences Announces Changes to Board of Directors

Newsfile January 8, 2021

Lobe Sciences Announces Jonathan Gilbert Appointed Executive Chairman of the Board of Directors

Newsfile December 14, 2020

Lobe Sciences Commences Engineering of Nasal Mist Device

Newsfile December 3, 2020

Lobe Sciences Announces CAD$23,000,000 Sale of Cowlitz Cannabis Option to Ionic Brands Corp.

Newsfile December 1, 2020

Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine

Newsfile November 30, 2020

Lobe Sciences Commences Trading Under New Name and Announces Rebranding and Corporate Update

Newsfile November 16, 2020

GreenStar Biosciences Announces Name Change

Newsfile November 11, 2020

GreenStar Biosciences Announces Stock Option Issuance

Newsfile October 28, 2020

GreenStar Biosciences Announces Launch of Science Advisory Board

Newsfile October 7, 2020

GreenStar Biosciences Announces New Provisional Patent Application

Newsfile September 14, 2020

GreenStar Biosciences Announces Filing of Fourth Provisional Patent Application

Newsfile August 5, 2020

GreenStar Biosciences' Partner Cowlitz Reports Revenues for Q1 2020

Newsfile July 29, 2020

GreenStar Biosciences Completes Acquisition of 100% of Eleusian Biosciences Corp. and Appoints Jonathan Gilbert to Board of Directors and Maghsoud Dariani as Chief Science Officer

Newsfile July 27, 2020

GreenStar Biosciences Announces Filing of Third Provisional Patent Application by Eleusian Biosciences

Newsfile July 23, 2020

GreenStar Biosciences Announces Closing of Private Placement and Debt Settlement

Newsfile July 23, 2020

GreenStar Biosciences Signs Definitive Agreement to Acquire 100% of Eleusian Biosciences Corp.

Newsfile July 21, 2020

GreenStar Biosciences Announces Non-Brokered Private Placement and Debt Settlement

Newsfile July 20, 2020

GreenStar Biosciences: Jonathan Gilbert, Eleusian Biosciences CEO, to Speak at Peak Asset Management's Psychedelic Investment Webinar

Newsfile June 17, 2020